Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination

V. Magri, E. Marras, V. Škerk, A. Markotić, A. Restelli, M. C. Garlaschi, G. Perletti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To investigate the association between eradication of Chlamydia trachomatis (CT) and symptom regression in chronic prostatitis, 55 symptomatic patients were subjected to segmented tests to localise CT in first voided urine (VB1), prostatic secretions (EPS), post-massage voided (VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral involvement' group ('U': VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg day-1 azithromycin for 3 days. The 'prostatitis' group ('P': VB1 negative, EPS/VB3/semen positive) with 4-week levofloxacin-azithromycin combination. A third group, 'U + P' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In P patients, eradication of CT was paralleled by marked, sustained symptom improvement and by significant decrease of serum prostate-specific antigen (PSA) levels. Compared with U patients, undergoing rapid regression of symptoms related to painful micturition after short-term azithromycin, U + P patients showed symptom and pathogen persistence in VB3/EPS/semen and required additional treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom regression, and decrease of PSA. Our results support a causative role of CT in chronic bacterial prostatitis. In the presence of a positive urethral localisation of the pathogen, thorough microbiological investigation together with focused symptom analysis may reveal an underlying chlamydial prostatitis and direct effective therapy with appropriate antibacterial agents.

Original languageEnglish
Pages (from-to)366-375
Number of pages10
JournalAndrologia
Volume42
Issue number6
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Prostatitis
Chlamydia trachomatis
Fluoroquinolones
Macrolides
Semen
Azithromycin
Levofloxacin
Prostate-Specific Antigen
Massage
Urination
Therapeutics
Urine
Anti-Bacterial Agents
Serum

Keywords

  • Chlamydia trachomatis
  • Chronic bacterial prostatitis
  • Chronic pelvic pain syndrome
  • NIH-CPSI
  • Prostatitis

ASJC Scopus subject areas

  • Urology
  • Endocrinology

Cite this

Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination. / Magri, V.; Marras, E.; Škerk, V.; Markotić, A.; Restelli, A.; Garlaschi, M. C.; Perletti, G.

In: Andrologia, Vol. 42, No. 6, 12.2010, p. 366-375.

Research output: Contribution to journalArticle

Magri, V. ; Marras, E. ; Škerk, V. ; Markotić, A. ; Restelli, A. ; Garlaschi, M. C. ; Perletti, G. / Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination. In: Andrologia. 2010 ; Vol. 42, No. 6. pp. 366-375.
@article{d5dc94ae88e343c9a25823fbd76dcf46,
title = "Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination",
abstract = "To investigate the association between eradication of Chlamydia trachomatis (CT) and symptom regression in chronic prostatitis, 55 symptomatic patients were subjected to segmented tests to localise CT in first voided urine (VB1), prostatic secretions (EPS), post-massage voided (VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral involvement' group ('U': VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg day-1 azithromycin for 3 days. The 'prostatitis' group ('P': VB1 negative, EPS/VB3/semen positive) with 4-week levofloxacin-azithromycin combination. A third group, 'U + P' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In P patients, eradication of CT was paralleled by marked, sustained symptom improvement and by significant decrease of serum prostate-specific antigen (PSA) levels. Compared with U patients, undergoing rapid regression of symptoms related to painful micturition after short-term azithromycin, U + P patients showed symptom and pathogen persistence in VB3/EPS/semen and required additional treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom regression, and decrease of PSA. Our results support a causative role of CT in chronic bacterial prostatitis. In the presence of a positive urethral localisation of the pathogen, thorough microbiological investigation together with focused symptom analysis may reveal an underlying chlamydial prostatitis and direct effective therapy with appropriate antibacterial agents.",
keywords = "Chlamydia trachomatis, Chronic bacterial prostatitis, Chronic pelvic pain syndrome, NIH-CPSI, Prostatitis",
author = "V. Magri and E. Marras and V. Škerk and A. Markotić and A. Restelli and Garlaschi, {M. C.} and G. Perletti",
year = "2010",
month = "12",
doi = "10.1111/j.1439-0272.2009.01033.x",
language = "English",
volume = "42",
pages = "366--375",
journal = "Andrologia",
issn = "0303-4569",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination

AU - Magri, V.

AU - Marras, E.

AU - Škerk, V.

AU - Markotić, A.

AU - Restelli, A.

AU - Garlaschi, M. C.

AU - Perletti, G.

PY - 2010/12

Y1 - 2010/12

N2 - To investigate the association between eradication of Chlamydia trachomatis (CT) and symptom regression in chronic prostatitis, 55 symptomatic patients were subjected to segmented tests to localise CT in first voided urine (VB1), prostatic secretions (EPS), post-massage voided (VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral involvement' group ('U': VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg day-1 azithromycin for 3 days. The 'prostatitis' group ('P': VB1 negative, EPS/VB3/semen positive) with 4-week levofloxacin-azithromycin combination. A third group, 'U + P' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In P patients, eradication of CT was paralleled by marked, sustained symptom improvement and by significant decrease of serum prostate-specific antigen (PSA) levels. Compared with U patients, undergoing rapid regression of symptoms related to painful micturition after short-term azithromycin, U + P patients showed symptom and pathogen persistence in VB3/EPS/semen and required additional treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom regression, and decrease of PSA. Our results support a causative role of CT in chronic bacterial prostatitis. In the presence of a positive urethral localisation of the pathogen, thorough microbiological investigation together with focused symptom analysis may reveal an underlying chlamydial prostatitis and direct effective therapy with appropriate antibacterial agents.

AB - To investigate the association between eradication of Chlamydia trachomatis (CT) and symptom regression in chronic prostatitis, 55 symptomatic patients were subjected to segmented tests to localise CT in first voided urine (VB1), prostatic secretions (EPS), post-massage voided (VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral involvement' group ('U': VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg day-1 azithromycin for 3 days. The 'prostatitis' group ('P': VB1 negative, EPS/VB3/semen positive) with 4-week levofloxacin-azithromycin combination. A third group, 'U + P' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In P patients, eradication of CT was paralleled by marked, sustained symptom improvement and by significant decrease of serum prostate-specific antigen (PSA) levels. Compared with U patients, undergoing rapid regression of symptoms related to painful micturition after short-term azithromycin, U + P patients showed symptom and pathogen persistence in VB3/EPS/semen and required additional treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom regression, and decrease of PSA. Our results support a causative role of CT in chronic bacterial prostatitis. In the presence of a positive urethral localisation of the pathogen, thorough microbiological investigation together with focused symptom analysis may reveal an underlying chlamydial prostatitis and direct effective therapy with appropriate antibacterial agents.

KW - Chlamydia trachomatis

KW - Chronic bacterial prostatitis

KW - Chronic pelvic pain syndrome

KW - NIH-CPSI

KW - Prostatitis

UR - http://www.scopus.com/inward/record.url?scp=78649556347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649556347&partnerID=8YFLogxK

U2 - 10.1111/j.1439-0272.2009.01033.x

DO - 10.1111/j.1439-0272.2009.01033.x

M3 - Article

C2 - 21105887

AN - SCOPUS:78649556347

VL - 42

SP - 366

EP - 375

JO - Andrologia

JF - Andrologia

SN - 0303-4569

IS - 6

ER -